Consensus recommendations on the use of botulinum toxin type a in facial aesthetics

被引:213
作者
Carruthers, J
Fagien, S
Matarasso, SL
机构
[1] Univ Calif San Francisco, Sch Med, Dept Dermatol, San Francisco, CA 94102 USA
[2] Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada
关键词
D O I
10.1097/01.PRS.0000144795.76040.D3
中图分类号
R61 [外科手术学];
学科分类号
摘要
The use of botulinum toxin type A for facial enhancement is the most common cosmetic procedure currently undertaken in the United States. Overall clinical and study experience with botulinum toxin type A treatment for facial enhancement has confirmed that it is effective and safe in both the short and long term. Nevertheless, consistent guidelines representing the consensus of experts for aesthetic treatments of areas other than glabellar lines have not been published. Therefore, a panel of experts on the aesthetic uses of Botox Cosmetic (botulinum toxin type A; Allergan, Inc., Irvine, Calif.) was convened to develop consensus guidelines. This publication comprises the recommendations of this panel and provides guidelines on general issues, such as the importance of the aesthetic evaluation and individualization of treatment, reconstitution and handling of the botulinum toxin type A, procedural considerations, dosing and injection-site variables, and patient selection and counseling. In addition, specific considerations and recommendations are provided by treatment area, including glabellar lines, horizontal forehead lines, "crow's feet," "bunny lines" (downward radiating lines on the sides of nose), the perioral area, the dimpled chin, and platysmal bands. The review of each area encompasses the relevant anatomy, specifics on injection locations and techniques, starting doses (total and per injection point), the influence of other variables, such as gender, and assessment and retreatment issues. Factors unique to each area are presented, and the discussion of each treatment area concludes with a review of key elements that can increase the likelihood of a successful outcome. Summary tables are provided throughout.
引用
收藏
页码:1S / 22S
页数:22
相关论文
共 61 条
[1]
Botulinum toxin A for the treatment of facial hyperkinetic wrinkle lines in Koreans [J].
Ahn, KY ;
Park, MY ;
Park, DH ;
Han, DG .
PLASTIC AND RECONSTRUCTIVE SURGERY, 2000, 105 (02) :778-784
[2]
Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative - A double-blind, randomized controlled trial [J].
Alam, M ;
Dover, JS ;
Arndt, KA .
ARCHIVES OF DERMATOLOGY, 2002, 138 (04) :510-514
[3]
Botulinum A exotoxin for hyperfunctional facial lines - Where not to inject [J].
Alam, M ;
Dover, JS ;
Klein, AW ;
Arndt, KA .
ARCHIVES OF DERMATOLOGY, 2002, 138 (09) :1180-1185
[4]
*ALL INC, BOT COSM BOT TOX TYP
[5]
Blitzer A, 1997, ARCH OTOLARYNGOL, V123, P389
[6]
BLITZER A, 1993, ARCH OTOLARYNGOL, V119, P1018
[7]
BLITZER A, 2002, TXB FACIAL REJUVENAT
[8]
BRANDT FS, 2004, 62 ANN M AM AC DERM
[9]
Long-term prospective follow-up of botulinum toxin treatment for facial rhytides [J].
Bulstrode, NW ;
Grobbelaar, AO .
AESTHETIC PLASTIC SURGERY, 2002, 26 (05) :356-359
[10]
Botulinum A exotoxin use in clinical dermatology [J].
Carruthers, A ;
Kiene, K ;
Carruthers, J .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (05) :788-797